Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Eric Lefkofsky, CEO and Chairman of Tempus AI , Inc. (NASDAQ:TEM), recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Lefkofsky disposed of shares valued at approximately $190.36 million. The transactions, which took place on February 27, involved the sale of 1,589,028 shares at a price of $58.75 per share. The timing is notable as InvestingPro data shows the stock has declined nearly 19% in the past week, with current trading levels suggesting overvaluation according to InvestingPro’s Fair Value model.
The sales were conducted through various entities associated with Lefkofsky, including Innovation Group Investors, L.P. and Lightbank Investments 1B, LLC, among others. These transactions have resulted in a reduction of his direct and indirect ownership in the company. Despite recent market volatility, Tempus AI maintains strong fundamentals with a healthy current ratio of 2.29 and impressive revenue growth of 30% over the last twelve months.
Despite these sales, Lefkofsky remains a key figure at Tempus AI, maintaining a significant presence in the company’s leadership as both CEO and Chairman. The company, headquartered in Chicago, specializes in data-driven decision-making tools for the healthcare industry. InvestingPro subscribers can access 8 additional key insights about Tempus AI, including detailed analysis of its $10.09 billion market capitalization and comprehensive financial health assessment.
In other recent news, Tempus AI Inc has reported a 35.8% year-over-year increase in fourth-quarter revenue, reaching $700 million, although the earnings per share (EPS) were negative at -0.18. The company has also completed its acquisition of Ambry Genetics, which is expected to contribute to a forecasted 2025 revenue of $1.24 billion. Despite a downgrade from JPMorgan, which revised its rating from Overweight to Neutral, the firm’s price target for Tempus AI was increased to $55, reflecting a raised revenue guidance. Stifel analysts maintained a Hold rating on Tempus AI, with a consistent price target of $65, following the company’s earnings report. The company’s core business is projected to grow over 30% year-over-year, driven by advances in diagnostic laboratory tests and genomics. Tempus AI’s strategic initiatives, such as the launch of the Olivia AI personal health app, are part of its efforts to expand its market presence. The company’s valuation remains a point of discussion among analysts, with comparisons drawn to industry peers like Natera Inc (NASDAQ:NTRA). and Guardant Health (NASDAQ:GH) Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.